Drug Advertising Restrictions Bill
Official: Responsibility in Drug Advertising Act of 2025
This bill aims to limit how drug companies advertise their products directly to consumers, especially soon after approval. It seeks to protect public health by ensuring that only safe drugs are promoted widely.
Health Care Efficiency Through Flexibility Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to delay certain requirements relating to the reporting of quality measures by accountable care organizations (ACOs) and to also test alternative reporting methods for ACOs. Specifically, the CMS must delay the requirement that ACOs use a specified electronic system for reporting quality measures until January 1, 2030. Additionally, the CMS must establish a pilot program to test other digital reporting methods; ACOs that participate in the pilot program are exempt from using the existing electronic system. The CMS must also implement standards for digital reporting by January 1, 2030, that ensure all electronic health record systems used by ACOs are able to support reporting across a range of practice sizes, specialties, and geographic locations. ACOs may use existing reporting methods until the standards are implemented.
1. This bill stops drug companies from advertising directly to consumers for the first three years after a drug is approved. 2. The Secretary of Health can allow advertising during the third year if it benefits public health. 3. After three years, the Secretary can ban advertising if the drug shows serious health risks. 4. The bill requires updates to drug advertising regulations within one year of becoming law.